Nabriva appoints Dr David Chiswell as CEO
This article was originally published in Scrip
Executive Summary
The Austrian biotechnology company Nabriva Therapeutics has appointed Dr David Chiswell as its chief executive officer. He succeeds George Golumbeski, who has left the company. Dr Chiswell has been involved with Nabriva since its foundation, having served as chairman of the supervisory board for the past three years. He founded and led Cambridge Antibody Technology from 1990 until 2002 (including as its CEO from 1996-2002). Since leaving CAT, Dr Chiswell has served on the boards of a number of biotech companies, including Arakis, Arrow Therapeutics, Daniolabs and Sosei. He currently serves as chairman of Albireo Pharma, a position which he will retain. Nabriva was founded in February 2006 as a spin-out of Sandoz.